| |
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now. 
|
|
|
Tuesday, January 31, 2023 | 11:00am ET This Webinar will highlight the comprehensive set of tools that Aldevron developed to support advancing mRNA projects to clinic. In addition, an overview of the technology transfer program, analytical and process characterization, release, and stability will be discussed with an insight into Aldevron’s integrated CMC capabilities ranging from transcript design and product profile definition through encapsulation and fill/finish. Register now. 
|
|
| By Zoey Becker Despite a possible safety concern for people 65 years and older who received Pfizer and BioNTech's updated COVID vaccine, the CDC says the signal is "very unlikely" to represent a true risk. |
|
|
|
By Max Bayer Many left last week’s J.P. Morgan Healthcare Conference a bit disappointed after relatively quiet M&A activity failed to wake up a bear industry slumbering through hibernation. Three separate mergers announced Tuesday show that many biotechs with a core asset are looking for new ways to survive. |
By Sharon Klahr Coey Pfizer’s new COVID-19 booster ad starring Martha Stewart is both odd and weirdly compelling to watch. |
By Nick Paul Taylor NewAmsterdam Pharma has advanced its bid to write a new chapter in the story of an Amgen castoff by linking the CETP inhibitor to reductions in LDL cholesterol when used as an adjunct to high-intensity statin therapy. The Dutch biotech plans to start a phase 3 trial on the strength of the data. |
|
Wednesday, January 25, 2023 | 1:00pm ET In this webinar, you’ll learn about a case study pursued in collaboration with Geneos Therapeutics and Personalis to utilize a tumor-informed ctDNA assay to retrospectively analyze clinical response to a class of personalized immunotherapies developed against tumor-specific neoantigens in advanced hepatocellular cancer (HCC) patients. Register now. 
|
|
By Angus Liu The strategy involves a comprehensive approach covering early research, drug profile selection, dealmaking, clinical development, plus commercialization and patient services, the company's U.S. head Victor Bulto said in an interview. |
By Conor Hale Illumina could well be facing the maximum fine the European Commission can impose, totaling up to 10% of its annual revenues, over the DNA sequencing giant’s premature acquisition of the blood testing company Grail, according to a report from Reuters. |
By Helen Floersh Experiments in mice, primates and human cells showed that Tessera's technology could edit and engineer genes to restore enzyme function, produce healthy hemoglobin and create CAR T cells. For their next trick, they'll do it all without ever removing cells from the body. |
By Angus Liu Roche’s pharma chief Bill Anderson is embarking on his next assignment outside the company. In search of his replacement, the Swiss pharma prefers an internal candidate, outgoing chairman Christoph Franz reportedly said. |
By Max Bayer J&J is packing up a global phase 3 trial of its HIV vaccine after failing to prevent infections compared to placebo. The news comes a year and a half after a different regimen of the vaccine failed a separate phase 2 trial in Africa. |
By Kevin Dunleavy National Resilience unveiled a plan to build a factory in the United Arab Emirates that will churn out a wide range of products, including therapeutics for cancer, inflammatory, infectious and autoimmune disorders as well as vaccines. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer. |
|
|---|
|
|
|
Thursday, February 2, 2023 | 11am ET/8am PT Regulators have made it abundantly clear - through recent guidance and inspection findings - that demonstrating sponsor oversight of an outsourced study is a critical requirement for TMF health and inspection-readiness. Join this webinar to discover how global biopharmaceutical company Chiesi and its CRO partners collaborate to ensure ongoing oversight compliance, in the face of increasing documentation requirements and trial complexity. Register now. 
|
|
Whitepaper RCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
